Xbiome Lands $10 Million In Series A Financing

According to VCBeat, Xbiome lands 10 million dollars in Series A financing. This rounds of financing was led by Li Xin Hong Capital and Ya Hui Capital.  

Xbiome was founded back in November 2017, it’s a pharmaceutical company for intestinal microecological treatment. Intestinal microecological disorders are associated with more than 50 diseases, including diabetes, obesity, cancer, autism and more. The so-called micro-ecological drugs are based on the results of these studies, using drugs made of microorganisms or other substances.

Xbiome has successfully established the world's largest library of intestinal flora for patients with gastrointestinal tumors that were treated with anti-PD-1 immunosuppressants in cooperation with Peking University Cancer Hospital. Xbiome's drug development team has experience in research and development of famous pharmaceutical and biotech companies such as Pfizer, Novartis and Bristol-Myers Squibb. The clinical team also has more than 20 years of experience in drug testing.

Xbiome has also established an AI-driven bacterial discovery platform that monitors microbial data through methods such as network analysis, machine learning and NLP. It can be used to pinpoint patient subtypes of bacteria.

Micro-ecological pharmacy is a new trend in the international pharmaceutical industry in recent years, especially in the field of many complex and chronic diseases. At present, the micro-ecological pharmacy boom has emerged worldwide.

An investment company founded back in 2016, it manages around 500 million RMB.

Ya Hui Capital is a professional fund specializing in the investment of the genetic testing industry.